A comprehensive review on early detection of drusen patterns in age-related macular degeneration using deep learning models

Age-related Macular Degeneration (AMD) is a leading cause of visual impairment and blindness that affects the eye from the age of fifty-five and older. It impacts on the retina, the light-sensitive layer of the eye. In early AMD, yellowish deposits called drusen, form under the retina, which could r...

Full description

Bibliographic Details
Published in:	Photodiagnosis and Photodynamic Therapy
Main Authors:	Kiruthika M, Malathi G
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Subjects:	Age-related Macular Degeneration (AMD) Drusen Fundus Color fundus photography (CFP) Dry AMD (dAMD) Neovascularization AMD (nAMD)
Online Access:	http://www.sciencedirect.com/science/article/pii/S1572100024004903

Similar Items

Seg-Swin: A Dual-Attention Transformer Model for Advanced AMD Classification and Lesion Detection Using Color Fundus Imaging
by: Niveen Nasr El-Den, et al.
Published: (2025-01-01)

The role of peripheral blood microRNAs in the pathogenesis and treatment response of age-related macular degeneration
by: Meng Kong, et al.
Published: (2025-12-01)

Off-Label Use of Bevacizumab in Patients Diagnosed with Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: João Estarreja, et al.
Published: (2024-07-01)

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF
by: H. Mhmud, et al.
Published: (2025-06-01)

Age-Related Macular Degeneration: Classification and Pathogenesis
by: İmren Akkoyun
Published: (2014-12-01)

Etiopathogenesis of non-exudative age-related macular degeneration (literature review)
by: M. M. Bikbov, et al.
Published: (2022-03-01)

Global Insights from Patients, Providers, and Staff on Challenges and Solutions in Managing Neovascular Age-Related Macular Degeneration
by: Anat Loewenstein, et al.
Published: (2024-12-01)

Biomarkers for the Progression of Intermediate Age-Related Macular Degeneration
by: Eleonora M. Lad, et al.
Published: (2023-09-01)

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
by: Reem H. ElSheikh, et al.
Published: (2022-11-01)

Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD)
by: Sonali Nashine
Published: (2021-09-01)

Patterns of Gene Expression, Splicing, and Allele-Specific Expression Vary among Macular Tissues and Clinical Stages of Age-Related Macular Degeneration
by: Treefa Shwani, et al.
Published: (2023-11-01)

A high-fat plus high-sucrose diet induces age-related macular degeneration in an experimental rabbit model
by: Yujiao Wang, et al.
Published: (2024-11-01)

Eye Drop with Fas-Blocking Peptide Attenuates Age-Related Macular Degeneration
by: Yujong Yi, et al.
Published: (2024-03-01)

Retinal Progression Biomarkers of Early and Intermediate Age-Related Macular Degeneration
by: Rita Flores, et al.
Published: (2021-12-01)

Deep Learning Approach for Age-related Macular Degeneration Detection Using Retinal Images: Efficacy Evaluation of Different Deep Learning Models
by: Ngoc Thien Le, et al.
Published: (2023-12-01)

Unusual visual loss in a patient with exudative macular degeneration
by: Enoch T. Peng, et al.
Published: (2022-06-01)

Dry and neovascular “wet” age-related macular degeneration: Upcoming therapies
by: Audrey Yan, et al.
Published: (2025-01-01)

Linking Adiponectin and Its Receptors to Age-Related Macular Degeneration (AMD)
by: Mayank Choubey, et al.
Published: (2023-11-01)

Early-onset macular drusen, a monogenic form of age-related macular degeneration
by: Lisa M. George, et al.
Published: (2025-09-01)

Age-Related Macular Degeneration: Therapeutic Strategies and Future Approaches
by: Răzvan Vasile ROPCIUC
Published: (2024-05-01)

Role of Optical Coherence Tomography Imaging in Predicting Progression of Age-Related Macular Disease: A Survey
by: Mohamed Elsharkawy, et al.
Published: (2021-12-01)

Genetic Insights into Age-Related Macular Degeneration
by: Bhumika, et al.
Published: (2024-07-01)

Efficacy and Safety of Aflibercept Biosimilars Relative to Reference Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
by: Aljuhani HS, et al.
Published: (2025-06-01)

Switching to brolucizumab: injection intervals and visual, anatomical and safety outcomes at 12 and 18 months in real-world eyes with neovascular age-related macular degeneration
by: Joseph M. Coney, et al.
Published: (2023-02-01)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
by: Praveen Yerramothu
Published: (2018-07-01)

Expanding Application of Optical Coherence Tomography Beyond the Clinic: A Narrative Review
by: Tutut Nurjanah, et al.
Published: (2025-04-01)

Morphological and functional retinal changes in neovascular age-related macular degeneration treated with intravitreal bevacizumab
by: Deepali R Damkondwar, et al.
Published: (2022-01-01)

Role of Complement in the Onset of Age-Related Macular Degeneration
by: Niloofar Piri, et al.
Published: (2023-05-01)

Brolucizumab in Pretreated Neovascular Age-Related Macular Degeneration: Case Series, Systematic Review, and Meta-Analysis
by: Christof Hänsli, et al.
Published: (2023-03-01)

Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration
by: Enrico Borrelli, et al.
Published: (2024-09-01)

Prevalence of insomnia and depression in patients with age-related macular degeneration
by: Elżbieta Nowak, et al.
Published: (2018-07-01)

Proteins Associated with Phagocytosis Alteration in Retinal Pigment Epithelial Cells Derived from Age-Related Macular Degeneration Patients
by: Audrey Voisin, et al.
Published: (2022-04-01)

Treatment of age related macular degeneration (AMD) currently and in the past
by: Klaudia Brożyna, et al.
Published: (2018-08-01)

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01)

Factors Affecting Disease Stability After Intravitreal Brolucizumab Injection for Refractory Neovascular Age-Related Macular Degeneration
by: Yung-Hwi Kim, et al.
Published: (2024-08-01)

First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration
by: Alaa Din Abdin, et al.
Published: (2022-05-01)

Aflibercept, ranibizumab, and bevacizumab for macular neovascularization secondary to age-related macular degeneration: a retrospective OCT-angiography study
by: Marco Lombardo, et al.
Published: (2025-10-01)

Real-World Frequency and Management of Ocular Adverse Events in Eyes with Neovascular Age-Related Macular Degeneration Treated with Brolucizumab
by: Ryan Zubricky, et al.
Published: (2023-06-01)

Mingjing granule inhibits the subretinal fibrovascular membrane of two-stage laser-induced neovascular age-related macular degeneration in rats
by: Xiaoyu Li, et al.
Published: (2024-06-01)

OCT Angiography-based Evaluation of the Choriocapillaris in Neovascular Age-related Macular Degeneration
by: Varsha Pramil, et al.
Published: (2021-10-01)